Physician profile
Pargol Samani
NPI 1881982486
$10,897.11
in general payments reported to CMS, 2019-2025
44 companies · $1,065 in 2025
The $1,065 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,105 · 2020: $868 · 2021: $2,117 · 2022: $1,997 · 2023: $2,100 · 2024: $1,646 · 2025: $1,065.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,810.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,810.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,785.59 | 2021-2025 | Linq II, Reveal Linq, Mycarelink |
| Amgen INC. | $1,230.07 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $830.00 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $814.17 | 2019-2025 | |
| Abbott Laboratories | $611.13 | 2021-2024 | Mitraclip, Freestyle Libre 3, Jot Dx |
| Janssen Pharmaceuticals, INC | $461.85 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $417.86 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $352.38 | 2021-2025 | Verquvo |
| Boston Scientific Corporation | $313.09 | 2019-2025 | Watchman Flx, Watchman Access System, Lux-Dx Insertable Cardiac Monitor |
| Astrazeneca Pharmaceuticals Lp | $305.84 | 2020-2025 | Farxiga, Wainua |
| Esperion Therapeutics, INC. | $218.99 | 2020-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $217.15 | 2020-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $198.55 | 2019-2024 | Eliquis |
| Actelion Pharmaceuticals US, INC. | $191.11 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Medtronic Vascular, INC. | $186.67 | 2019 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $170.80 | 2021-2023 | Biomonitor |
| Shockwave Medical, INC | $142.03 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Bayer Healthcare Pharmaceuticals INC. | $135.20 | 2021-2025 | |
| Kiniksa Pharmaceuticals, Ltd. | $125.09 | 2021-2023 | Arcalyst |
| Otsuka America Pharmaceutical, INC. | $120.72 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $119.31 | 2019-2023 | Lifevest |
| Novo Nordisk INC | $95.30 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Arbor Pharmaceuticals, INC. | $93.80 | 2021-2022 | |
| Irhythm Technologies, INC. | $86.48 | 2019-2022 | |
| Daiichi Sankyo INC. | $74.24 | 2023-2024 | Injectafer |
| Alnylam Pharmaceuticals INC. | $64.76 | 2022-2023 | Amvuttra |
| Lilly USA, LLC | $64.06 | 2023-2025 | Mounjaro, Zepbound |
| Baxter Healthcare | $62.57 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Kiniksa Pharmaceuticals International, Plc | $47.96 | 2024 | Arcalyst |
| Angiodynamics, INC. | $33.36 | 2020 | |
| Kestra Medical Technology Services, INC. | $33.09 | 2023 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $31.47 | 2019 | |
| Heartflow, INC. | $29.47 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $28.55 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.12 | 2019 | |
| Akcea Therapeutics, INC. | $25.78 | 2020 | |
| Itamar Medical INC | $24.09 | 2024 | Watchpatone |
| Philips North America LLC | $22.97 | 2024 | (5044) Mcot |
| Athena Bioscience, LLC | $21.69 | 2025 | Nexiclon Xr |
| Altathera Pharmaceuticals LLC | $20.28 | 2024 | Sotalol Hydrochloride |
| Vivaquant INC, Dba Rhythm Express | $19.40 | 2025 | Rhythm Express |
| Azurity Pharmaceuticals, INC. | $17.67 | 2025 | Edarbi |
| Bardy Diagnostics, INC. | $15.00 | 2019 | |
| Eisai INC. | $11.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pargol Samani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.